In May 2018 Health Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other gadolinium contrast injections for MRIs, CT scans, and other radiology procedures. In May 2018 Health Canada issued this document, “Summary Safety Review – Gadolinium based contrast agents – Assessing the … [Read more...]
MRI Contrast Agents: Gadolinium Retention Warnings Added To Drug Label
The gadolinium contrast agents safety warnings announced by the FDA in December 2017 started to be seen on new drug labels approved in the spring of 2018. It is important to understand that symptoms of gadolinium-related medical conditions can first appear anywhere from just a few hours until several weeks after the MRI or MRA procedure when a … [Read more...]